Intact Investment Management Inc. Acquires 72,300 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Intact Investment Management Inc. grew its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC) by 38.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 261,300 shares of the company’s stock after buying an additional 72,300 shares during the period. Intact Investment Management Inc. owned approximately 0.07% of Bausch Health Companies worth $2,112,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Goldentree Asset Management LP boosted its holdings in shares of Bausch Health Companies by 31.0% during the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock worth $239,552,000 after buying an additional 6,958,717 shares in the last quarter. Bank of Montreal Can boosted its holdings in shares of Bausch Health Companies by 234.0% during the 3rd quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock worth $31,598,000 after buying an additional 2,685,675 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Bausch Health Companies by 62.0% during the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock worth $26,614,000 after buying an additional 1,263,706 shares in the last quarter. Maple Rock Capital Partners Inc. bought a new position in shares of Bausch Health Companies during the 3rd quarter worth approximately $16,850,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Bausch Health Companies by 1.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,284,036 shares of the company’s stock worth $10,375,000 after buying an additional 14,558 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Jefferies Financial Group reiterated a “hold” rating and issued a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada cut their target price on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $7.42.

Bausch Health Companies Trading Up 3.7 %

NYSE BHC opened at $7.15 on Friday. The firm has a market capitalization of $2.63 billion, a P/E ratio of -59.54, a PEG ratio of 0.37 and a beta of 0.59. The business has a fifty day simple moving average of $7.22 and a 200 day simple moving average of $7.63. Bausch Health Companies Inc. has a 12 month low of $3.96 and a 12 month high of $11.46.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). The company had revenue of $2.56 billion during the quarter, compared to analysts’ expectations of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. As a group, sell-side analysts predict that Bausch Health Companies Inc. will post 4.41 EPS for the current fiscal year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.